We are live on ! Find out more
CUAMC

China Universal Asset Management Company Portfolio holdings

AUM $1.67B
1-Year Est. Return 89%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
10 Year Est. Return
AUM
$514M
AUM Growth
+$169M
Cap. Flow
+$103M
Cap. Flow %
19.96%
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$4.85M
2
ADI icon
Analog Devices
ADI
+$3.37M
3
AMZN icon
Amazon
AMZN
+$3.21M
4
LULU icon
lululemon athletica
LULU
+$2.87M
5
ORCL icon
Oracle
ORCL
+$1.91M

Sector Composition

Rank Sector Weight
1 Technology 34.39%
2 Healthcare 30.05%
3 Consumer Discretionary 17.55%
4 Communication Services 6.11%
5 Consumer Staples 4.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
H icon
401
Hyatt Hotels
H
$16.8B
$31.3K 0.01%
240
-3,100
-93% -$352K
AVIR icon
402
Atea Pharmaceuticals
AVIR
$405M
$29.4K 0.01%
9,653
+7,514
+351% +$22.8K
VNDA icon
403
Vanda Pharmaceuticals
VNDA
$314M
$28.1K 0.01%
6,658
+5,186
+352% +$20.9K
PAHC icon
404
Phibro Animal Health
PAHC
$1.37B
$27.3K 0.01%
2,357
+1,843
+359% +$20.8K
ATAI icon
405
AtaiBeckley Inc
ATAI
$2.68B
$27.1K 0.01%
19,206
+14,948
+351% +$18.6K
OVID icon
406
Ovid Therapeutics
OVID
$489M
$26.3K 0.01%
+8,178
New +$28K
VLTO icon
407
Veralto
VLTO
$23.6B
$23.9K ﹤0.01%
+290
New +$21.7K
CRL icon
408
Charles River Laboratories
CRL
$13.6B
$21K ﹤0.01%
89
RGEN icon
409
Repligen
RGEN
$9.35B
$20.7K ﹤0.01%
115
EW icon
410
Edwards Lifesciences
EW
$53.6B
$19.5K ﹤0.01%
256
IQV icon
411
IQVIA
IQV
$39.8B
$19.4K ﹤0.01%
84
BLUE
412
DELISTED
bluebird bio
BLUE
$17.5K ﹤0.01%
632
+495
+361% +$30.2K
VTYX
413
DELISTED
Ventyx Biosciences
VTYX
$16.9K ﹤0.01%
6,832
+5,326
+354% +$50.6K
EXAS
414
DELISTED
Exact Sciences
EXAS
$16K ﹤0.01%
216
EL icon
415
Estee Lauder
EL
$31.7B
$14.5K ﹤0.01%
99
-1,300
-93% -$173K
ACRS icon
416
Aclaris Therapeutics
ACRS
$860M
$8.61K ﹤0.01%
8,196
+6,382
+352% +$19.5K
OKUR
417
OnKure Therapeutics
OKUR
$159M
$6.17K ﹤0.01%
+386
New +$24.1K
TXRH icon
418
Texas Roadhouse
TXRH
$14.1B
$5.38K ﹤0.01%
44
KR icon
419
Kroger
KR
$34.3B
$2.74K ﹤0.01%
60
RL icon
420
Ralph Lauren
RL
$23.6B
$2.32K ﹤0.01%
16
NIU
421
Niu Technologies
NIU
$162M
$2.19K ﹤0.01%
1,000
HSY icon
422
Hershey
HSY
$37B
$1.86K ﹤0.01%
10
JD icon
423
JD.com
JD
$42.7B
$1.85K ﹤0.01%
64
-1,690
-96% -$45.8K
CPRI icon
424
Capri Holdings
CPRI
$1.77B
$402 ﹤0.01%
8
FTCH
425
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
$174 ﹤0.01%
7,800

Similar funds

China Universal Asset Management Company's Q4 2023 Portfolio in Review

As of Q4 2023, China Universal Asset Management Company held 503 positions worth $514M, up 49% from $345M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

China Universal Asset Management Company deployed $103M of net new capital in Q4 2023, opening 57 new positions and adding to 239 existing holdings. Its largest new stake was GSK: 54,345 shares worth $2.03M.

By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was NVIDIA, an estimated $4.85M trimmed.

  • China Universal Asset Management Company's largest Q4 2023 buy was GSK: 54,345 shares worth $2.03M.
  • China Universal Asset Management Company added most to Vertex Pharmaceuticals in Q4 2023, an estimated $6.25M increase.
  • China Universal Asset Management Company's biggest Q4 2023 reduction was NVIDIA, cutting an estimated $4.85M.
  • China Universal Asset Management Company fully exited Oracle in Q4 2023, selling an estimated $1.91M.
  • China Universal Asset Management Company's ten largest holdings make up 27% of its $514M portfolio in Q4 2023.
  • China Universal Asset Management Company opened 57 new positions and closed 78 in Q4 2023.
  • China Universal Asset Management Company's portfolio value rose 49% quarter-over-quarter to $514M.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.